论文部分内容阅读
目的评价双时相 ~(18)F-脱氧葡萄糖(FDG)符合线路显像在肿瘤良恶性鉴别诊断中的应用价值。方法对100例临床拟诊为恶性肿瘤的患者,静脉注射~(18)F-FDG 185～370 MBq 后40～65min 和100～140min,采用 Philips IREX 三探头符合线路 SPECT 仪分别行早期和延迟显像。测定2次显像病灶(L)和对侧正常组织(B)的感兴趣区(ROI)放射性计数,并计算 L/B 比值和 L/B 变化率(△L/B)。结果最后经病理检查或临床随访证实恶性肿瘤75例,良性病变25例。恶性肿瘤组早期显像 L/B 比值为3.62±2.07,延迟显像为5.67±3.20,△L/B 为(57.59±31.91)%;良性病生组2次显像的 L/B 比值分別为2.47±1.53(早期)和2.72±1.93(延迟),△L/B 为(7.23±23.14)%。以△L/B>30%作为良恶性病变鉴别诊断的阈值,灵敏度为97.3%,特异性为92.0%,准确性为96.0%。结论恶性肿瘤延迟显像 L/B 比值的增高幅度明显大于良性病变,且双时相符合线路显像方法简便、实用,能提高~(18)F-FDG 符合线路显像鉴別良恶性病变的灵敏度、特异性和准确性,有较高的临床应用价值。
Objective To evaluate the value of ~ (18) F-deoxyglucose (FDG) coincidence imaging in the differential diagnosis of benign and malignant tumors. Methods 100 cases of clinically suspected malignant tumors were treated with Philips IREX three-probe line coincidence SPECT instrument with intravenous injection of ~ (18) F-FDG 185 ~ 370 MBq 40 ~ 65min and 100 ~ 140min respectively Like The area of interest (ROI) radioactivity was counted in two imaging lesions (L) and the contralateral normal tissue (B), and the L / B ratio and L / B rate of change (△ L / B) were calculated. Results The final pathological examination or clinical follow-up confirmed 75 cases of malignant tumors, benign lesions in 25 cases. The L / B ratio of early imaging in malignant tumor group was 3.62 ± 2.07, delayed imaging was 5.67 ± 3.20, and △ L / B was (57.59 ± 31.91)%. The ratio of L / B in second imaging of benign disease group was 2.47 ± 1.53 (early) and 2.72 ± 1.93 (delayed), △ L / B was (7.23 ± 23.14)%. To △ L / B> 30% as the differential diagnosis of benign and malignant lesions threshold, the sensitivity was 97.3%, the specificity was 92.0%, the accuracy of 96.0%. Conclusions The increase of L / B ratio in delayed imaging of malignant tumor is obviously larger than that of benign lesions, and the double coincidence line imaging method is simple and practical, which can improve the differentiation of benign and malignant lesions with ~ (18) F-FDG coincidence imaging. Sensitivity, specificity and accuracy, a higher clinical value.